Form 4: Vigil Neuroscience Director Koenig Awarded Stock Options

Director Gerhard Koenig of Vigil Neuroscience, Inc. received stock options for 18,068 shares at an exercise price of $3.38 on June 5, 2024.

Summary

• On June 5, 2024, Gerhard Koenig, a director of Vigil Neuroscience, Inc., was granted stock options to purchase 18,068 shares of common stock.
• The exercise price for these options is $3.38 per share.
• The options vest and become exercisable on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders.
• The options expire on June 5, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as the granting of stock options is a standard practice and can be seen as a positive sign of aligning management interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards the company's success.

Industry Context

Stock option awards are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in biotech companies like Vigil Neuroscience.
• Comparable companies such as Biogen, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term value creation.

Stakeholder Impact

• The stock option award could potentially impact shareholders by diluting equity if the options are exercised.
• It incentivizes the director to work towards increasing shareholder value.

Key Dates